High-risk cytogenetics in multiple myeloma (FISH)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-MM-CYTOGENETICS-HR |
|---|---|
| Type | Biomarker |
| Aliases | High-risk cytogenetics in multiple myeloma by interphase FISHHochrisiko-Zytogenetik MMMM HR FISHЦитогенетика високого ризику при множинній мієломі (FISH) |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-MM-2025 |
Biomarker Facts
| Biomarker type | gene_fusion |
|---|---|
| Measurement | MethodInterphase FISH on CD138-enriched plasma cells Unitscategorical (positive | negative for each abnormality) |
| Related biomarkers | BIO-TP53-MUTATION |
Notes
Composite biomarker — "positive" if ANY of the following present per IMWG / R-ISS / R2-ISS conventions: t(4;14), t(14;16), t(14;20), del(17p)/TP53 loss, gain or amplification of 1q21. t(11;14) is NOT high-risk (standard-risk). Drives treatment intensification — the algorithm's primary determinant for selecting quadruplet (D-VRd) over triplet (VRd) in transplant-eligible 1L MM.
Used By
Biomarker
BIO-TP53-MUTATION- TP53 mutation / del(17p)
Questionnaires
QUEST-MM-1L- Multiple Myeloma — newly diagnosed (1L)
Red flag
RF-MM-HIGH-RISK-CYTOGENETICS- Multiple myeloma high-risk cytogenetics: any of t(4;14), t(14;16), t(14;20), del(17p)/TP5...